PALB2
合成致死
同源重组
DNA修复
生殖系
BRCA2蛋白
乳腺癌
奥拉帕尼
聚ADP核糖聚合酶
医学
遗传学
癌症研究
种系突变
支票2
基因组不稳定性
基因
突变
生物
聚合酶
癌症
作者
Chi-Cheng Huang,Ling-Ming Tseng
标识
DOI:10.1245/s10434-022-11407-5
摘要
Poly(ADP-ribose) polymerase (PARP) inhibitors selectively cause the failure of DNA single-stranded break (SSB) repair but do not affect double-stranded break (DSB) repair. Furthermore, antitumor activities have been reported for breast cancer, with germline BRCA1/2 mutations. The prevalence of germline BRCA1/2 mutations never exceed one-tenth; beyond BRCA1/2, genes recurrently altered (more than 5%) in the homologous repair pathway are ARID1A, PALB2, and PTEN. Altered homologous recombination repair genes can total up to one-quarter based on different definitions, and the potential of PARP inhibitors will be elucidated when further studies unraveling the impact of individual homologous recombination genes are conducted.
科研通智能强力驱动
Strongly Powered by AbleSci AI